Scientists announced the results of the iPrex trial in November 2010, showing that overall, a daily dose of Truvada, a combination of two oral antiretroviral drugs, tenofovir disoproxil fumarate and emtricitabine, reduced HIV infection in a sample of high-risk men who have sex with men (MSM) and transgender (TG) women by 44 percent. Among those […]
Read More